Optimization of Prostate Biopsy Referral Decisions

References

• Alagoz O, Maillart LM, Schaefer AJ, Roberts MS. The optimal timing of living-donor liver transplantation. Management Sci. (2004) 50(10):1420–1430Link, Google Scholar
• Albright SC. Structural results for partially observable Markov decision processes. Oper. Res. (1979) 27(5):1041–1053Link, Google Scholar
• American Cancer Society American Cancer Society guidelines for the early detection of cancer. (2010a) . Accessed August 7, 2011, http://www.cancer.org/Healthy/FindCancerEarly/CancerScreening Guidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancerGoogle Scholar
• American Cancer SocietyCancer Facts and Figures 2010 (2010b) (American Cancer Society, Atlanta) . Accessed January 1, 2011, http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-and-figures-2010Google Scholar
• American Urological AssociationProstate-Specific Antigen Best Practice Statement: 2009 Update (2009) (American Urological Association, Linthicum, MD) . Accessed February 1, 2011, http://www.auanet.org/content/guidelines-and-qualitycare/clinical-guidelines/main-reports/psa09.pdfGoogle Scholar
• Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, Fouad MN, et al. Mortality results from a randomized prostate-cancer screening trial. New England J. Medicine (2009) 360(13):1310–1319Crossref, Google Scholar
• Arias E. United States life tables, 2006. Natl. Vital Statist. Rep. (2010) 58(21):1–40Google Scholar
• Ashley RA, Inman BA, Routh JC, Mynderse LA, Gettman MT, Blute ML. Reassessing the diagnostic yield of saturation biopsy of the prostate. Eur. Urology (2008) 53(5):976–981Crossref, Google Scholar
• Astrom K. Optimal control of Markov processes with incomplete state information. J. Math. Anal. Appl. (1965) 10(1):174–205Crossref, Google Scholar
• Aus G, Robinson D, Rosell J, Sandblom G, Varenhorst EGroup South-East Region Prostate Cancer Group. Group South-East Region Prostate Cancer Group Survival in prostate carcinoma—outcomes from a prospective, population-based cohort of 8,887 men with up to 15 years of follow-up: Results from three countries in the population-based national prostate cancer registry of Sweden. Cancer (2005a) 103(5):943–951Crossref, Google Scholar
• Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid H-P, van Poppelf H, Wolff J, Zattoni F. EAU guidelines on prostate cancer. Eur. Urology (2005b) 48(4):546–551Crossref, Google Scholar
• Barry MJ. Screening for prostate cancer—the controversy that refuses to die. New England J. Medicine (2009) 360(13):1351–1354Crossref, Google Scholar
• Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer (2004) 101(9):2001–2005Crossref, Google Scholar
• Begg CB, Greenes RA. Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics (1983) 39(1):207–215Crossref, Google Scholar
• Brandeau ML, Owens DK, Sox CH, Wachter RM. Screening women of childbearing age for human-immunodeficiency-virus—A model-based policy analysis. Mangement Sci. (1993) 39(1):72–92Link, Google Scholar
• Bremner KE, Chong CAKY, Tomlinson G, Alibhai SMH, Krahn MD. A review and meta-analysis of prostate cancer utilities. Medical Decision Making (2007) 27(3):288–298Crossref, Google Scholar
• Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Human Pathol. (2000) 31(5):578–583Crossref, Google Scholar
• Burkhardt JH, Litwin MS, Rose CM, Correa RJ, Sunshine JH, Hogan C, Hayman JA. Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer. J. Clinical Oncology (2002) 20(12):2869–2875Crossref, Google Scholar
• Cassandra AR, Littman ML, Zhang NL. Incremental pruning: A simple, fast, exact method for partially observable Markov decision processes. Proc. Thirteenth Annual Conf. Uncertainty in Artificial Intelligence (UAI-97) (1997) (Morgan Kaufmann, San Francisco) 54–61Google Scholar
• Chhatwal J, Alagoz O, Burnside ES. Optimal breast biopsy decision making based on mammographic features and demographic factors. Oper. Res. (2010) 58(6):1577–1591Link, Google Scholar
• Chon CH, Lai FC, McNeal JE, Presti JC. Use of extended systematic sampling in patients with a prior negative prostate needle biopsy. J. Urology (2002) 167(6):2457–2460Crossref, Google Scholar
• Denton BT, Kurt M, Shah ND, Bryant SC, Smith SA. Optimizing the start time of statin therapy for patients with diabetes. Medical Decision Making (2009) 29(3):351–367Crossref, Google Scholar
• Epstein JI, Sanderson H, Carter H B, Scharfstein DO. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology (2005) 66(2):356–360Crossref, Google Scholar
• Etzioni R, Gulati R, Falcon S, Penson DF. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: A surveillance modeling approach. Medical Decision Making (2008) 28(3):323–331Crossref, Google Scholar
• Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J. Natl. Cancer Inst. (2002) 94(13):981–990Crossref, Google Scholar
• Fall K, Garmo H, Andrewn O, Bill-Axelson A, Adolfsson J, Adami H, Johansson J, Holmberg L. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J. Natl. Cancer Inst. (2007) 99(7):526–532Crossref, Google Scholar
• Fanshel S, Bush JW. A health status index and its application to health-services outcomes. Oper. Res. (1970) 18(6):1021–1066Link, Google Scholar
• Ghani KR, Grigor K, Tulloch DN, Bollina PR, McNeill SA. Trends in reporting Gleason score 1991 to 2001: Changes in the pathologist's practice. Eur. Urology (2005) 47(2):196–201Crossref, Google Scholar
• Gold MR, Stevenson D, Fryback DG. HALYs and QALYs and DALYs, oh my: Similarities and differences in summary measures of population health. Annual Rev. Publ. Health (2002) 23:115–134Crossref, Google Scholar
• Haas GP, Delongchamps NB, Jones RF, Chandan V, Serio AM, Vickers AJ, Jumbelic M, et al. Needle biopsies on autopsy prostates: Sensitivity of cancer detection based on true prevalence. J. Natl. Cancer Inst. (2007) 99(19):1484–1489Crossref, Google Scholar
• Hamilton AS, Albertsen PC, Johnson TK, Hoffman R, Morrell D, Deapen D, Penson DF. Trends in the treatment of localized prostate cancer using supplemented cancer registry data. British J. Urology Internat. (2011) 107(4):576–584Crossref, Google Scholar
• Hauskrecht M, Fraser H. Planning treatment of ischemic heart disease with partially observable Markov decision processes. Artif. Intell. Medicine (2000) 18(3):221–244Crossref, Google Scholar
• Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology (1997) 50(2):239–243Crossref, Google Scholar
• Holmström B, Johansson M, Bergh A, Stenman U-H, Hallmans G, Stattin P. Prostate specific antigen for early detection of prostate cancer: Longitudinal study. British Medical J. (2009) 339:b3537Crossref, Google Scholar
• Hu C, Lovejoy WS, Shafer SL. Comparison of some suboptimal control policies in medical drug therapy. Oper. Res. (1993) 44(5):696–709Link, Google Scholar
• Inman BA, Zhang J, Shah ND, Denton BT. An examination of the dynamic changes in prostate-specific antigen occurring in a population-based cohort of men over time. British J. Urology Internat. (2012) . ePub ahead of print February 7, doi:10.111/j.1464-410X.2011.10925.xGoogle Scholar
• Ivy JS. A maintenance model for breast cancer treatment and detection. (2008) . Working paper, Edward P. Fitts Department of Industrial and Systems Engineering, North Carolina State University, RaleighGoogle Scholar
• Kawachi MH, Bahnson RR, Barry M, Busby JE, Carroll PR, Carter HB, Catalona WJ, et al. NCCN clinical practice guidelines in oncology: Prostate cancer early detection. J. Natl. Comprehensive Cancer Network (2010) 8(2):240–262Crossref, Google Scholar
• Krahn M, Ritvo P, Irvine J, Tomlinson G, Bremner KE, Bezjak A, Trachtenberg J, Naglie G. Patient and community preferences for outcomes in prostate cancer: Implications for clinical policy. Medical Care (2003) 41(1):153–164Crossref, Google Scholar
• Kulkarni GS, Alibhai SM, Finelli A, Fleshner NE, Jewett MA, Lopushinsky SR, Bayoumi AM. Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer (2009) 115(23):5450–5459Crossref, Google Scholar
• Lee EK, Gallagher RJ, Silvern D, Wu C, Zaider M. Treatment planning for brachytherapy: An integer programming model, two computational approaches, and experiments with permanent prostate implant planning. Phys. Medical Biol. (1999) 44(1):145–165Crossref, Google Scholar
• Lee HL, Pierskalla WP. Mass-screening models for contagious-diseases with no latent period. Oper. Res. (1988) 36(6):917–928Link, Google Scholar
• Lovejoy WS. Some monotonicity results for partially observed Markov decision processes. Oper. Res. (1987) 35(5):736–743Link, Google Scholar
• Madsen KA, Bennett JE, Downs SM. The role of parental preferences in the management of fever without source among 3- to 36-month-old children: A decision analysis. Pediatrics (2006) 117(4):1067–1076Crossref, Google Scholar
• Maillart LM, Ivy JS, Ransom S, Diehl K. Assessing dynamic breast cancer screening policies. Oper. Res. (2008) 56(6):1411–1427Link, Google Scholar
• Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, Partin AW. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology (2007) 69(6):1095–1101Crossref, Google Scholar
• Master VA, Chi T, Simko JP, Weinberg V, Carroll PR. The independent impact of extended pattern biopsy on prostate cancer stage migration. J. Urology (2005) 174(5):1789–1793Crossref, Google Scholar
• Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D. Eastern Cooperative Oncology Group Study EST 3886 Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. (2006) 7(6):472–479Crossref, Google Scholar
• Monahan GE. A survey of partially observable Markov decision processes: Theory, models, and algorithms. Management Sci. (1982) 28(1):1–16Link, Google Scholar
• National Cancer Institute Surveillance Epidemiology and End Results (SEER). SEER stat fact sheets, cancer: Prostate. (2009) . Accessed November 9, http://seer.cancer.gov/statfacts/html/prost.htmlGoogle Scholar
• Nguyen CT, Yu C, Moussa A, Kattan MW, Jones JS. Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy. J. Urology (2010) 183(2):529–533Crossref, Google Scholar
• O'Connor AM, Bennett CL, Stacey D, Barry M, Col NF, Eden KB, Entwistle VA, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst. Rev. (2009) 3:CD001431Google Scholar
• Packer A. Applying cost-effectiveness concepts to the community health system. Oper. Res. (1968) 16(2):227–253Link, Google Scholar
• Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. J. Amer. Medical Assoc. (1997) 277(18):1445–1451Crossref, Google Scholar
• Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. New England J. Medicine (2003) 349(4):335–342Crossref, Google Scholar
• Rabets JC, Jones JS, Patel A, Zippe CD. Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J. Urology (2004) 172(1):94–97Crossref, Google Scholar
• Roobol MJ, Grenabo J, Schröder FH, Hugosson J. Interval cancers in prostate cancer screening: Comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J. Natl. Cancer Inst. (2007) 99(17):1296–1303Crossref, Google Scholar
• Ross KS, Carter HB, Pearson JD, Guess HA. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. J. Amer. Medical Assoc. (2000) 284(11):1399–1405Crossref, Google Scholar
• Rubin DL, Burnside ES, Shachter R, Brandeau ML, Sainfort F, Pierskalla WP. A Bayesian network to assist mammography interpretation. Operations Research and Healthcare: A Handbook of Methods and Applications (2004) (Kluwer Academic, Boston) 695–720Chap. 27Google Scholar
• Sandblom G, Carlsson P, Sennfält K, Varenhorst E. A population-based study of pain and quality of life during the year before death in men with prostate cancer. British J. Cancer (2004) 90(6):1163–1168Crossref, Google Scholar
• Scardino PT, Beck JR, Miles BJ. Conservative management of prostate cancer. New England J. Medicine (1994) 330(25):1830–1832Crossref, Google Scholar
• Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, Kwiatkowski M, et al. Screening and prostate-cancer mortality in a randomized European study. New England J. Medicine (2009) 360(13):1320–1328Crossref, Google Scholar
• Schwartz JS, Kinosian BP, Pierskalla WP, Lee H. Strategies for screening blood for human-immunodeficiency-virus antibody—Use of a decision support system. J. Amer. Medical Assoc. (1990) 264(13):1704–1710Crossref, Google Scholar
• Shechter SM, Bryce CL, Alagoz O, Kreke JE, Stahl JE, Schaefer AJ, Angus DC, Roberts MS. A clinically based discrete event simulation of end-stage liver disease and the organ allocation process. Medical Decision Making (2005) 25(2):199–209Crossref, Google Scholar
• Sofer A, Zeng J, Mun SK. Optimal biopsy protocols for prostate cancer. Ann. Oper. Res. (2003) 119(1–4):63–74Crossref, Google Scholar
• Sommers BD, Beard CJ, D'Amico AV, Dahl D, Kaplan I, Richie JP, Zeckhauser RJ. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer. Cancer (2007) 110(10):2210–2217Crossref, Google Scholar
• Sondik EJ. The optimal control of partially observable Markov processes. (1971) . Ph.D. thesis, Stanford University, Stanford, CAGoogle Scholar
• Tchetgen MB, Song JT, Strawderman M, Jacobsen SJ, Oesterling JE. Ejaculation increases the serum prostate-specific antigen concentration. Urology (1996) 47(4):511–516Crossref, Google Scholar
• Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA. Assessing prostate cancer risk: Results from the prostate cancer prevention trial. J. Natl. Cancer Inst. (2006) 98(8):529–534Crossref, Google Scholar
• Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. New England J. Medicine (2004) 350(22):2239–2246Crossref, Google Scholar
• U.S. Preventive Services Task Force Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Internal Medicine (2008) 149(3):185–191Crossref, Google Scholar
• van der Cruijsen-Koeter IW, van der Kwast TH, Schröder FH. Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)–Rotterdam. J. Natl. Cancer Inst. (2003) 95(19):1462–1466Crossref, Google Scholar
• Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J. Natl. Cancer. Inst. (2011) 103(6):462–469Crossref, Google Scholar
• Wein LM, Zenios SA. Pooled testing for HIV screening: Capturing the dilution effect. Oper. Res. (1996) 44(4):543–569Link, Google Scholar
• Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J. Natl. Cancer Inst. (2009) 101:1325–1329Crossref, Google Scholar
• Welch HG, Black WC. Overdiagnosis in cancer. J. Natl. Cancer Inst. (2010) 102(9):605–613Crossref, Google Scholar
• White CC. Monotone control laws for noisy, countable state Markov chains. Eur. J. Oper. Res. (1980) 5(2):124–132Crossref, Google Scholar
• Woolf SH, Rothemich SF. Screening for prostate cancer: The roles of science, policy, and opinion in determining what is best for patients. Annual Rev. Medicine (1999) 50:207–221Crossref, Google Scholar
• Wright JC, Weinstein MC. Gains in life expectancy from medical interventions–standardizing data on outcomes. New England J. Medicine (1998) 339(6):380–386Crossref, Google Scholar
• Zhang NL, Liu W. Planning in stochastic domains: Problem characteristics and approximation. (1996) . Technical report HKUST-CS96-31, Department of Computer Science, Hong Kong University of Science and Technology, KowloonGoogle Scholar